Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26982000 | 0.90 | USP30 (0.47) | MAPTPOLBMKNK1HDAC2HDAC1 | |
| SCHEMBL26981973 | 0.79 | MAPT (0.38) | MAPTTACR1KDM4EPOLBMKNK1 | |
| SCHEMBL21777896 | 0.78 | MAPT (0.46) | MAPTTACR1KDM4ECYP2C19HPGD | |
| SCHEMBL21788825 | 0.76 | MAPT (0.51) | MAPTTACR1HDAC2HDAC1USP30 | |
| SCHEMBL21788887 | 0.75 | MAPT (0.47) | MAPTTACR1HDAC1CYP2C19CYP2D6 | |
| SCHEMBL29789103 | 0.75 | MAPT (0.47) | MAPTTACR1HDAC1CYP2C19CYP2D6 | |
| SCHEMBL29116459 | 0.75 | MAPT (0.40) | MAPTPOLBUSP30CYP2C19CYP1A2 | |
| SCHEMBL17605822 | 0.75 | DNMT3A (0.44) | MAPTKDM4EHDAC2HDAC1CYP2C19 | |
| SCHEMBL26981969 | 0.74 | MAPT (0.45) | MAPTTACR1CYP2C19NPSR1HTT | |
| SCHEMBL26981989 | 0.72 | POLB (0.37) | MAPTTACR1POLBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725486-A2 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | Cytokinetics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12286437-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240132498-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | CYTOKINETICS, INCORPORATED | 2024-04-25 | — | — | US | disclosed |
| WO-2024050539-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | CYTOKINETICS, INCORPORATED (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11919909-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4301760-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117083275-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20220306642-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022187501-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919909-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | MAPT 268/4885TACR1 2513/4885KDM4E 2730/4885 |
| US-12286437-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | MAPT 268/4885TACR1 2513/4885KDM4E 2730/4885 |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, TNNC1 | MAPT 268/4885TACR1 2513/4885KDM4E 2730/4885 |
| US-20220306642-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, TNNC1 | MAPT 268/4885TACR1 2513/4885KDM4E 2730/4885 |
| US-20240132498-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | UACA, TUBA3C, CA5B | MAPT 916/4885TACR1 4504/4885KDM4E 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.